切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2024, Vol. 13 ›› Issue (06) : 818 -824. doi: 10.3877/cma.j.issn.2095-3232.2024030

临床研究

肝细胞癌TACE术后复发影响因素及预测模型建立
公宇1, 廖媛2, 尚梅2,()   
  1. 1.510060 广州,中山大学肿瘤防治中心内镜科
    2.510630 广州,中山大学附属第三医院检验科
  • 收稿日期:2024-07-22 出版日期:2024-12-10
  • 通信作者: 尚梅
  • 基金资助:
    广东省基础与应用基础研究联合基金(2020A1515110152)

Influencing factors and prediction model for recurrence of hepatocellular carcinoma after TACE

Yu Gong1, Yuan Liao2, Mei Shang2,()   

  1. 1.Department of Endoscopy,Sun Yat-sen University Cancer Center,Guangzhou 510060,China
    2.Clinical Laboratory,the Third Affiliated Hospital of Sun Yat-sen University,Guangzhou 510630,China
  • Received:2024-07-22 Published:2024-12-10
  • Corresponding author: Mei Shang
引用本文:

公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.

Yu Gong, Yuan Liao, Mei Shang. Influencing factors and prediction model for recurrence of hepatocellular carcinoma after TACE[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 818-824.

目的

探讨肝细胞癌(肝癌)患者TACE术后1年内复发的危险因素,并构建列线图预测模型。

方法

回顾性分析2021年8月至2022年8月在中山大学附属第三医院首次行TACE的85例肝癌初诊患者临床资料。患者均签署知情同意书,符合医学伦理学规定。其中男78例,女7例;平均年龄(58±12)岁。肝癌CNLC分期Ⅰb期22例,Ⅱa期12例,Ⅱb期24例,Ⅲa期9例,Ⅲb期18例;肿瘤直径1.5~19.2 cm,中位直径6.0 cm;多发49例,单发36例。按TACE术后短期复发状态分为短期预后良好组和短期预后不良组,收集两组一般临床资料及检验指标等相关资料,Cox回归分析短期预后影响因素,采用R语言构建列线图模型。绘制校准曲线,同时进行模型内部验证。采用ROC曲线下面积(AUC)评估该模型的预测价值,使用决策曲线分析(DCA)评估该模型的临床价值。

结果

Cox单因素回归分析显示,AFP(HR=5.055,95%CI:2.224~11.490)、肝硬化(HR=6.261,95%CI:1.862~21.060)、IL-6差值(HR=0.409,95%CI:0.171~0.979)和C-反应蛋白(CRP)差值(HR=2.905,95%CI:1.158~7.287)与TACE术后短期复发有关(P<0.05);Cox多因素回归分析显示,AFP≥400 μg/L(HR=3.722,95%CI:1.543~8.978)、肝硬化(HR=4.406,95%CI:1.249~15.548),IL-6差值≥18.79 pg/ml(HR=0.312,95%CI:0.119~0.819),CRP差值≥36.67 mg/L(HR=4.967,95%CI:1.895~13.021)是TACE术后短期复发的独立危险因素(P<0.05)。基于独立危险因素绘制列线图模型,模型内部验证显示预测TACE术后复发的一致性指数(C-index)为0.875(95%CI:0.842~0.907),分辨度良好;ROC曲线分析该模型预测术后1年无复发生存的AUC为0.794,DCA评估该模型的临床价值,提示该模型的净获益值大,临床价值比较高。

结论

AFP、肝硬化、IL-6差值和CRP差值是TACE治疗的肝癌患者术后短期复发的独立危险因素,以此为指标成功构建了预测TACE术后复发的列线图模型,该模型在预判肝癌患者复发情况具有一定的实用价值。

Objective

To investigate the risk factors of recurrence in patients with hepatocellular carcinoma (HCC) within 1 year after TACE,and establish a nomogram prediction model.

Methods

Clinical data of 85 patients newly diagnosed with HCC who underwent transarterial chemoembolization(TACE) for the first time in the Third Affiliated Hospital of Sun Yat-sen University from August 2021 to August 2022 were retrospectively analyzed. The informed consents of all patients were obtained and the local ethical committee approval was received. Among them,78 patients were male and 7 female,aged (58±12) years on average. According to the China liver cancer (CNLC) staging system,22 patients were classified as CNLC stage Ⅰb,12 cases of stage Ⅱa,24 cases of stage Ⅱb,9 cases of stage Ⅲa and 18 cases of stage Ⅲb,respectively. The tumor diameter was ranged from 1.5 to 19.2 cm,with a median diameter of 6.0 cm. 49 cases had multiple tumors and 36 cases with single tumor. According to patients' situation of short-term recurrence after TACE,all patients were divided into the favorable and poor prognosis groups. Clinical data and detection parameters in two groups were collected. Cox's regression model was used to analyze the influencing factors of short-term prognosis,and R language was adopted to establish the nomograph model.The calibration curve was delineated and internal validation of the prediction model was performed. The area under the receiver operating characteristic (ROC) curve (AUC) was employed to evaluate the predictive value of this model. Decision curve analysis (DCA) was adopted to evaluate the clinical value of this model.

Results

Univariate Cox's regression analysis showed that AFP (HR=5.055,95%CI: 2.224-11.490),liver cirrhosis (HR=6.261,95%CI: 1.862-21.060) and differences of IL-6 levels (HR=0.409,95%CI: 0.171-0.979)and differences of C-reactive protein (CRP) levels (HR=2.905,95%CI: 1.158-7.287) were correlated with short-term recurrence after TACE (P<0.05). Multiple Cox's regression analysis showed that AFP≥400 μg/L(HR=3.722,95%CI: 1.543-8.978),liver cirrhosis (HR=4.406,95%CI: 1.249-15.548) and the differences of IL-6 levels≥18.79 pg/ml (HR=0.312,95%CI: 0.119-0.819) and the differences of CRP levels≥36.67 mg/L(HR=4.967,95%CI: 1.895-13.021) were the independent risk factors of short-term recurrence after TACE(P<0.05). A nomogram model was drawn based on these independent risk factors. Internal validation of this model showed that the concordance index (C-index) for predicting the recurrence of HCC after TACE was 0.875 (95%CI: 0.842-0.907),and the degree of discrimination was high. ROC curve analysis revealed that the AUC of this model for predicting 1-year recurrence-free survival was 0.794. DCA demonstrated that this model had large net benefit value and relatively high clinical value.

Conclusions

AFP,liver cirrhosis,the differences of IL-6 and CRP levels are the independent risk factors for postoperative short-term recurrence in HCC patients after TACE. Based on these parameters,a nomogram model for predicting postoperative recurrence of HCC is successfully established,which has certain practical value in predicting the recurrence of HCC.

图1 肝癌患者TACE术后复发的Cox单因素分析森林图 注:CRP 为C-反应蛋白,PCT为降钙素原,APOA为载脂蛋白A,APOB为载脂蛋白B,LPA为脂蛋白A,LDH为乳酸脱氢酶
图2 肝癌患者TACE术后复发的Cox多因素分析森林图 注:CRP 为C-反应蛋白
图3 肝癌患者TACE术后复发列线图预测模型 注:CRP 为C-反应蛋白
图4 肝癌患者TACE术后复发列线图预测模型的校准曲线
图5 肝癌患者TACE术后1年短期无复发生存的ROC曲线 注:AUC为曲线下面积
图6 肝癌患者TACE术后复发列线图预测模型的决策曲线分析
[1]
Yang JD,Hainaut P,Gores GJ,et al. A global view of hepatocellular carcinoma: trends,risk,prevention and management[J]. Nat Rev Gastroenterol Hepatol,2019,16(10):589-604.
[2]
阿力木江·买合木提,冷超,徐磊,等. APRI在肝细胞癌淋巴结转移术后患者预后中的价值[J/OL]. 中华肝脏外科手术学电子杂志,2020,9(6):529-532.
[3]
Sung H,Ferlay J,Siegel RL,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
[4]
中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024 年版)[J/OL]. 中华肝脏外科手术学电子杂志,2024,13(4):407-449.
[5]
Duran R,Sharma K,Dreher MR,et al. A novel inherently radiopaque bead for transarterial embolization to treat liver cancer - a pre-clinical study[J]. Theranostics,2016,6(1):28-39.
[6]
Artinyan A,Nelson R,Soriano P,et al. Treatment response to transcatheter arterial embolization and chemoembolization in primary and metastatic tumors of the liver[J]. HPB,2008,10(6):396-404.
[7]
Lu LH,Wei W,Li SH,et al. The lymphocyte-C-reactive protein ratio as the optimal inflammation-based score in patients with hepatocellular carcinoma underwent TACE[J]. Aging,2021,13(4):5358-5368.
[8]
Cucchetti A,Cappelli A,Golfieri R. Reply to external validation of an individual prognostic calculator after trans-arterial chemoembolization for hepatocellular carcinoma[J]. Liver Int,2016,36(8):1232.
[9]
Minici R,Siciliano MA,Ammendola M,et al. Prognostic role of neutrophil-to-lymphocyte ratio (NLR),lymphocyte-to-monocyte ratio (LMR),platelet-to-lymphocyte ratio (PLR) and lymphocyteto-C reactive protein ratio (LCR) in Patients with hepatocellular carcinoma (HCC) undergoing chemoembolizations (TACE) of the liver: the unexplored corner linking tumor microenvironment,biomarkers and interventional radiology[J]. Cancers,2022,15(1):257.
[10]
Calderaro J,Petitprez F,Becht E,et al. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma[J]. J Hepatol,2019,70(1):58-65.
[11]
石凤翔,李晓雯,柳青,等. 肝切除术与肝动脉化疗栓塞术治疗伴大血管侵犯肝细胞癌成本效果分析[J]. 中华肿瘤防治杂志,2019,26(9):603-608.
[12]
Komorowski AL,Hsu CC,Julka KD,et al. AFP role in predicting recurrence of hepatocellular carcinoma after living donor liver transplantation in HCV patients[J]. Neoplasma,2018,65(3):455-460.
[13]
Golfieri R,Cappelli A,Cucchetti A,et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small(<5 cm) hepatocellular carcinomas[J]. Hepatology,2011,53(5):1580-1589.
[14]
中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作专业委员会,中华医学会肝病学会肝癌学组,等. 原发性肝癌规范化病理诊断方案专家共识[J]. 临床肝胆病杂志,2011,27(4):343-345.
[15]
刘华江,邓堂,颜运智,等. 术前NLR联合AFP对肝细胞癌患者TACE术后预后的预测价值[J]. 中国临床医学影像杂志,2019,30(10):716-720,747.
[16]
蔡越飞,王凯,冼重杨,等. AFP和MKP-1对无法切除的肝细胞癌患者经TACE术治疗的预后预测价值[J]. 国际消化病杂志,2021,41(6):427-432.
[17]
罗清兰,邓宇伟,曾涛. 原发性肝癌术前中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值和甲胎蛋白对预后的评估分析[J]. 当代医学,2022,28(19):18-21.
[18]
Mehrpour M,Afrakhte M,Shojaei SF,et al. Factors predicting the outcome of intravenous thrombolysis in stroke patients before rt-PA administration[J]. Caspian J Intern Med,2019,10(4):424-430.
[19]
Vaclavik D,Vilionskis A,Jatuzis D,et al. Clinical outcome of cardioembolic stroke treated by intravenous thrombolysis[J]. Acta Neurol Scand,2018,137(3):347-355.
[20]
鲍乐,李鹏飞,王友彬,等. 晚期肝癌TACE术后再次复发的风险因素分析[J]. 中国现代医生,2021,59(34):1-3,7.
[21]
赵露,姜文雯,张馨,等. 原发性肝癌患者肝动脉化疗栓塞术前行肝硬化CT分级对术后1年中位生存期和生存率的影响[J]. 肝脏,2018,23(12):1117-1119.
[22]
Wang J,Chen Z,Wang L,et al. A new model based inflammatory index and tumor burden score (TBS) to predict the recurrence of hepatocellular carcinoma (HCC) after liver resection[J]. Sci Rep,2022,12(1):8670.
[23]
Wang D,Bai N,Hu X,et al. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC[J].PeerJ,2019,7:e7132.
[24]
Schrader J,Iredale JP. The inflammatory microenvironment of HCC -the plot becomes complex[J]. J Hepatol,2011,54(5):853-855.
[25]
Sanghera C,Teh JJ,Pinato DJ. The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma[J]. Liver Int,2019,39(11):2008-2023.
[26]
张迪铭,葛海蓉. C反应蛋白和降钙素原检测在恶性肿瘤患者感染性疾病中的应用[J]. 中国肿瘤临床与康复,2022,29(1):73-75.
[27]
杜成荣,丁德权,曹齐生,等. 老年原发性肝癌患者TACE术后发生肝功能代偿不全的影响因素[J]. 中国老年学杂志,2022,42(11):2648-2651.
[28]
Meischl T,Rasoul-Rockenschaub S,Györi G,et al. C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation[J]. PLoS One,2019,14(5):e0216677.
[29]
Lokken RP,Kerlan RK,Chung YC,et al. Hepatic toxicity after selective chemoembolization is associated with decreased survival among patients with hepatocellular carcinoma[J]. AJR Am J Roentgenol,2021,216(5):1283-1290.
[30]
Zhao X,Dou J,Cao J,et al. Uncovering the potential differentially expressed miRNAs as diagnostic biomarkers for hepatocellular carcinoma based on machine learning in The Cancer Genome Atlas database[J]. Oncol Rep,2020,43(6):1771-1784.
[31]
Loosen SH,Schulze-Hagen M,Leyh C,et al. IL-6 and IL-8 serum levels predict tumor response and overall survival after TACE for primary and secondary hepatic malignancies[J]. Int J Mol Sci,2018,19(6):1766.
[1] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[2] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[3] 奚玲, 仝瀚文, 缪骥, 毛永欢, 沈晓菲, 杜峻峰, 刘晔. 基于肌少症构建的造口旁疝危险因素预测模型[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 48-51.
[4] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[5] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[6] 谢田伟, 庞于樊, 吴丽. 超声引导下不同消融术对甲状腺良性结节体积缩减率、复发率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 80-83.
[7] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[8] 刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[9] 陈宗杰, 胡添松. 肝外伤破裂患者治疗后胆漏发生影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 836-840.
[10] 焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[11] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[12] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[13] 吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[14] 韦巧玲, 黄妍, 赵昌, 宋庆峰, 陈祖毅, 黄莹, 蒙嫦, 黄靖. 肝癌微波消融术后中重度疼痛风险预测列线图模型构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 715-721.
[15] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
阅读次数
全文


摘要